Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: Improved survival in sequential studies

Amerigo Boiardi, Antonio Silvani, Annalisa Pozzi, Laura Fariselli, Giovanni Broggi, Andrea Salmaggi

Research output: Contribution to journalArticle

Abstract

We investigated the efficacy of 3 different systemic chemotherapy regimes in 122 patients with histologically confirmed glioblastoma, KPS > 60, age <65. Locoregional chemotherapy was delivered to 22 patients from all three systemic chemotherapy groups. Chemotherapy was given before and during radiotherapy, which was the same for all patients consisting of unconventional fractionation with a break between courses. Survival (Kaplan-Meier) was significantly longer in the subgroup receiving cisplatinum plus BCNU compared to those receiving cisplatinum plus etoposide or carboplatinum plus BCNU with median survival time 21.5 months, 15 months and 15 months respectively (log rank test p = 0.01). Survival was also significantly longer in patients who received locoregional therapy compared to those who received only systemic chemotherapy (21 vs 15 months, p = 0.01). Univariate analysis showed that age, postoperative Karnofsky status and extent of resection were not predicitve of survival in the series, although there were trends to better outcome in younger patients and those undergoing total/subtotal resection. Age, systemic chemotherapy type and interstitial treatment were included in a multivariate analysis, and both locoregional treatment and chemotherapy with cisplatinum plus BCNU were significantly predictive of survival [P = 0.01]. These encouraging preliminary results suggest that further trials with locoregional and systemic therapy prior to radiotherapy are worth pursuing.

Original languageEnglish
Pages (from-to)151-157
Number of pages7
JournalJournal of Neuro-Oncology
Volume41
Issue number2
DOIs
Publication statusPublished - 1999

Fingerprint

Glioblastoma
Drug Therapy
Survival
Carmustine
Radiotherapy
Etoposide
Therapeutics
Multivariate Analysis

Keywords

  • Glioblastoma
  • Loco-regional chemotherapy
  • Prognostic factors

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients : Improved survival in sequential studies. / Boiardi, Amerigo; Silvani, Antonio; Pozzi, Annalisa; Fariselli, Laura; Broggi, Giovanni; Salmaggi, Andrea.

In: Journal of Neuro-Oncology, Vol. 41, No. 2, 1999, p. 151-157.

Research output: Contribution to journalArticle

@article{a195fbb8199f48ff91bee1ec35c767ba,
title = "Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: Improved survival in sequential studies",
abstract = "We investigated the efficacy of 3 different systemic chemotherapy regimes in 122 patients with histologically confirmed glioblastoma, KPS > 60, age <65. Locoregional chemotherapy was delivered to 22 patients from all three systemic chemotherapy groups. Chemotherapy was given before and during radiotherapy, which was the same for all patients consisting of unconventional fractionation with a break between courses. Survival (Kaplan-Meier) was significantly longer in the subgroup receiving cisplatinum plus BCNU compared to those receiving cisplatinum plus etoposide or carboplatinum plus BCNU with median survival time 21.5 months, 15 months and 15 months respectively (log rank test p = 0.01). Survival was also significantly longer in patients who received locoregional therapy compared to those who received only systemic chemotherapy (21 vs 15 months, p = 0.01). Univariate analysis showed that age, postoperative Karnofsky status and extent of resection were not predicitve of survival in the series, although there were trends to better outcome in younger patients and those undergoing total/subtotal resection. Age, systemic chemotherapy type and interstitial treatment were included in a multivariate analysis, and both locoregional treatment and chemotherapy with cisplatinum plus BCNU were significantly predictive of survival [P = 0.01]. These encouraging preliminary results suggest that further trials with locoregional and systemic therapy prior to radiotherapy are worth pursuing.",
keywords = "Glioblastoma, Loco-regional chemotherapy, Prognostic factors",
author = "Amerigo Boiardi and Antonio Silvani and Annalisa Pozzi and Laura Fariselli and Giovanni Broggi and Andrea Salmaggi",
year = "1999",
doi = "10.1023/A:1006119505170",
language = "English",
volume = "41",
pages = "151--157",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Springer New York LLC",
number = "2",

}

TY - JOUR

T1 - Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients

T2 - Improved survival in sequential studies

AU - Boiardi, Amerigo

AU - Silvani, Antonio

AU - Pozzi, Annalisa

AU - Fariselli, Laura

AU - Broggi, Giovanni

AU - Salmaggi, Andrea

PY - 1999

Y1 - 1999

N2 - We investigated the efficacy of 3 different systemic chemotherapy regimes in 122 patients with histologically confirmed glioblastoma, KPS > 60, age <65. Locoregional chemotherapy was delivered to 22 patients from all three systemic chemotherapy groups. Chemotherapy was given before and during radiotherapy, which was the same for all patients consisting of unconventional fractionation with a break between courses. Survival (Kaplan-Meier) was significantly longer in the subgroup receiving cisplatinum plus BCNU compared to those receiving cisplatinum plus etoposide or carboplatinum plus BCNU with median survival time 21.5 months, 15 months and 15 months respectively (log rank test p = 0.01). Survival was also significantly longer in patients who received locoregional therapy compared to those who received only systemic chemotherapy (21 vs 15 months, p = 0.01). Univariate analysis showed that age, postoperative Karnofsky status and extent of resection were not predicitve of survival in the series, although there were trends to better outcome in younger patients and those undergoing total/subtotal resection. Age, systemic chemotherapy type and interstitial treatment were included in a multivariate analysis, and both locoregional treatment and chemotherapy with cisplatinum plus BCNU were significantly predictive of survival [P = 0.01]. These encouraging preliminary results suggest that further trials with locoregional and systemic therapy prior to radiotherapy are worth pursuing.

AB - We investigated the efficacy of 3 different systemic chemotherapy regimes in 122 patients with histologically confirmed glioblastoma, KPS > 60, age <65. Locoregional chemotherapy was delivered to 22 patients from all three systemic chemotherapy groups. Chemotherapy was given before and during radiotherapy, which was the same for all patients consisting of unconventional fractionation with a break between courses. Survival (Kaplan-Meier) was significantly longer in the subgroup receiving cisplatinum plus BCNU compared to those receiving cisplatinum plus etoposide or carboplatinum plus BCNU with median survival time 21.5 months, 15 months and 15 months respectively (log rank test p = 0.01). Survival was also significantly longer in patients who received locoregional therapy compared to those who received only systemic chemotherapy (21 vs 15 months, p = 0.01). Univariate analysis showed that age, postoperative Karnofsky status and extent of resection were not predicitve of survival in the series, although there were trends to better outcome in younger patients and those undergoing total/subtotal resection. Age, systemic chemotherapy type and interstitial treatment were included in a multivariate analysis, and both locoregional treatment and chemotherapy with cisplatinum plus BCNU were significantly predictive of survival [P = 0.01]. These encouraging preliminary results suggest that further trials with locoregional and systemic therapy prior to radiotherapy are worth pursuing.

KW - Glioblastoma

KW - Loco-regional chemotherapy

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=0032945048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032945048&partnerID=8YFLogxK

U2 - 10.1023/A:1006119505170

DO - 10.1023/A:1006119505170

M3 - Article

C2 - 10222435

AN - SCOPUS:0032945048

VL - 41

SP - 151

EP - 157

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -